Telix Pharmaceuticals
TLX10.0600.40% ( -0.040 )
Telix Pharmaceuticals (TLX)
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radi...
- Open
- 10.040
- High
- 10.060
- Low
- 9.935
- Prev. Close
- 10.100
- Volume
- 68.37K
- Turnover
- 684.37K
- Avg Price
- 10.010
- Bid/Ask Ratio
- --
- Amplitude
- 1.24%
- 52wk High
- 14.270
- Volume Ratio
- 0.39
- Turnover Ratio
- 0.03%
Telix Pharmaceuticals Analyst Rating
View MoreForecast & Rating
Jul 28, 2026Price forecast
$20.89107.62%
Forecast & RatingStrong buy
5analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- rttnews · Jul 21 at 12:45 AM
Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business
- Simplywall · Jul 21 at 12:09 AM
3 Australian Growth Stocks Trading Below Fair Value With Strong Insider Backing
- businessinsider · Jul 20 at 11:30 PM
Telix Pharmaceuticals reports Q2 results; updates FY2026 outlook
- Tip Ranks · Jul 20 at 07:35 PM
Bell Potter Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
- PUBT · Jul 20 at 05:48 PM
Telix appoints three new non-executive directors to expanded board
- Quartr · Jul 20 at 05:41 PM
TLX: Q2 2026 revenue up 21% YoY to US $247M, with FY 2026 revenue expected to surpass US $1B
